Checkpoint Therapeutics, Inc. (CKPT) News
Filter CKPT News Items
CKPT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CKPT News Highlights
- For CKPT, its 30 day story count is now at 5.
- Over the past 14 days, the trend for CKPT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CKPT are DRUG, DEC and CRL.
Latest CKPT News From Around the Web
Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit OutlookWe feel now is a pretty good time to analyse Checkpoint Therapeutics, Inc.'s ( NASDAQ:CKPT ) business as it appears the... |
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapyCheckpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. Checkpoint said the FDA did not state any concerns about the data or safety on the drug in its so-called complete response letter. |
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party ManufacturerFDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimabWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma |
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023Some of the most explosive opportunities can be found in biotech stocks. |
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent IssuanceUpcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC |
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsBiologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights. “The J |
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of CancerCosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma Biologics License Application review ongoing; PDUFA goal date of January 3, 2024 WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pub |
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross ProceedsWALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.0 |
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare ConferenceWALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City. The Company will also attend in-person one-on-one meetings during the conference. A webcast of the |
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceWALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference. A webcast |